Myriad Logo
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us

News Releases

Nov 11, 2019
Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening
Pipeline
Nov 09, 2019
New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis
Pipeline
Nov 01, 2019
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting
Products
Oct 28, 2019
Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
Products
Oct 08, 2019
Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting
Pipeline
Sep 16, 2019
Myriad Announces Research Collaboration with University of Leeds
Pipeline
Sep 05, 2019
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment
Pipeline
Aug 22, 2019
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention
Products
Aug 07, 2019
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
Pipeline
Jun 27, 2019
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
Products
Jun 03, 2019
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
Products
Jun 02, 2019
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
Pipeline
May 09, 2019
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy
Pipeline
May 01, 2019
Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®
Pipeline
Apr 09, 2019
Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test
Pipeline
Previous
Next page
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
    • Investor Day
  • News
    • Press Releases
    • Email Alerts Subscription
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.